Presence of 5α-Reductase isozymes and aromatase in human prostate cancer cells and in benign prostate hyperplastic tissue

Prostate

Volumn 34, Issue 4, 1998, Pages 283-291

  Negri Cesi, Paola ^a,b   Poletti, Angelo ^a   Colciago, Alessandra ^a   Magni, Paolo ^a   Martini, Paolo ^a   Motta, Marcella ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Department of Endocrinology ^*  (Italy)

Author keywords

5 reductase; Aromatase; Benign prostate hyperplasia; LNCaP cells

Indexed keywords

AROMATASE; ESTROGEN; STEROID 5ALPHA REDUCTASE; ISOENZYME;

ARTICLE; ENZYME ANALYSIS; ENZYME LOCALIZATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; ANIMAL; BIOSYNTHESIS; CELL CULTURE; ENZYMOLOGY; GENETICS; PATHOLOGY; PROSTATE TUMOR; RABBIT;

ANIMALS; AROMATASE; HUMANS; ISOENZYMES; MALE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RABBITS; TESTOSTERONE 5-ALPHA-REDUCTASE; TUMOR CELLS, CULTURED;

EID: 0031594509     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19980301)34:4<283::AID-PROS6>3.0.CO;2-I     Document Type: Article

References (40)

1. Cunha GR, Donjacour AA, Cooke PS, Mee S, Bigsby RM, Higgins SJ, Sugimura Y: The endocrinology and developmental biology of the prostate. Endocr Rev 1987;8:338-362.
2. Motta M, Serio M: "Sex Hormones and Antihormones in Endocrine-Dependent Pathology: Basic and Clinical Aspects." Amsterdam: Excerpta Medica, 1994.
3. Wilding G: The importance of steroid hormones in prostate cancer. Cancer Surv 1992;14:113-130.
4. Motta M, Zoppi S, Brodie AM, Martini L: Effect of 1,4,6-androstatriene-3,17-dione (ATD), 4-hydroxy-4-androstene-3,17-dione (4-OH-A) and 4-acetoxy-4-androstene-3,17-dione (4-Ac-A) on the 5α-reduction of androgens in the rat prostate. J Steroid Biochem 1986;25:593-600.
5. Henttu P, Liao S, Vihko P: Androgens up-regulate the human prostate-specific antigen messenger ribonucleic acid (mRNA), but down-regulate the prostate acid phosphatase mRNA in LN-CaP cell line. Endocrinology 1992;130:766-772.
6. Lee CL, Sutkowski DM, Sensibar JA, Zelner D, Kim I, Amsel I, Shaw N, Prins GS, Kozlowski JM: Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. Endocrinology 1995;136:796-803.
7. Bologna M, Muzi P, Biordi L, Festuccia C, Vicentini C: Finasteride dose-dependently reduces the proliferation rate of LNCaP human prostate cancer cell line. Urology 1995;45:282-290.
8. Rennie PS, Bruchovsky N, Mcloughlin MG, Batzold FH, Dunstal-Adams EE: Kinetic analysis of 5α-reductase isoenzymes in benign prostatic hyperplasia (BPH). J Steroid Biochem 1983;19: 169-173.
9. Martini L, Zoppi S, Motta M: Studies on the possible existence of two 5α-reductases in the rat prostate. J Steroid Biochem 1986; 24:177-182.
10. Andersson S, Russell DW: Structural and biochemical properties of cloned and expressed human and rat 5α-reductases. Proc Natl Acad Sci USA 1990;87:3640-3644.
11. Jenkins EP, Andersson S, Imperato-McGinley J, Wilson JD, Russell DW: Genetic and pharmacological evidence for more than one human steroid 5α-reductase. J Clin Invest 1992;89:293-300.
12. Russell DW, Wilson JD: Steroid 5α-reductase: Two genes/two enzymes. Ann Rev Biochem 1994;63:25-61.
13. Thigpen AE, Cala KM, Russel DW: Characterization of Chinese hamster ovary cell line expressing human steroid 5α-reductase isozymes. J Biol Chem 1993;268:17404-17412.
14. Bonnet P, Reiter E, Bruyninx M, Sente B, Dombrowicz D, de Leval J, Closset J, Hennen G: Benign prostatic hyperplasia and normal prostate aging: Differences in types 1 and 2 5α-reductase and steroid hormone receptor messenger ribonucleic acid (mRNA) levels, but not insulin-like growth factor mRNA. J Clin Endocrinol Metab 1993;77:1203-1208.
15. Dlos S, Carsol JL, Ghazarossian E, Raynaud JP, Martin PM: Testosterone metabolism in primary cultures of human prostate epithelial cells and fibroblasts. J Steroid Biochem Mol Biol 1995; 55:375-383.
16. Thigpen AE, Silver RI, Guileyardo JM, Casey ML, McConnell JD, Russel DW: Tissue distribution and ontogeny of steroid 5α-reductase isozyme expression. J Clin Invest 1993;92:903-910.
17. Silver RI, Wiley EL, Davis DL, Thigpen AE, Russel DW, McConnell JD: Expression and regulation of 5α-reductase 2 in prostate disease. J Urol 1994;152:433-437.
18. Juniewicz PE, Lemb BM, Berbolt TA, Labrie TK, Batzold FH, Reel JR: Dose-dependent hormonal induction of BPH in castrated dog. Prostate 1989;14:341-352.
19. Kirschenbaum A, Ren M, Erenburg I, Schachter B, Levine AC: Estrogen receptor messenger RNA expression in human benign prostate hyperplasia: Detection, localization, and modulation with long-acting gonadotropin-releasing hormone agonist. J Androl 1994;15:528-533.
20. Murphy J, Emmott RC, Hicks LL, Walsh PC: Estrogen receptors UT the human prostate, seminal vesicles, epididymis, testis and genital skin: A marker for estrogen-responsive tissues? J Clin Endocrinol Metab 1980;50:938-947.
21. Ekman P, Barrack ER, Greene GL, Jensen EV, Walsh PC: Estrogen receptors in human prostate: Evidence for multiple binding sites. J Clin Endocrinol Metab 1983;57:166-176.
22. Donnelly BJ, Lakey WH, McBlain WA: Estrogen receptors in human benign prostatic hyperplasia. J Urol 1983;130:183-187.
23. Castagnetta LA, Miceli MD, Sorci CMG, Pfeffer U, Farruggio R, Olivieri G, Calabr M, Carruba G: Growth of LNCaP human prostate cancer cells is stimulated by estradiol via its own receptor. Endocrinology 1995;136:2309-2319.
24. Berns EMJJ, de Boer W, Mulder E: Androgen-dependent growth regulation of and release of specific protein(s) by the androgen receptor containing human prostate tumor cell line LNCaP. Prostate 1986;9:247-259.
25. Stone NN, Fair WR, Fishman J: Estrogen formation in human prostatic tissue from patients with and without benign prostatic hyperplasia. Prostate 1986;9:311-318.
26. Block JL, Block NL, Lokeshwar BL: Inhibition of aromatase activity and growth suppression by 4-methoxy-4-androstene-3,17-dione in an androgen sensitive human prostatic carcinoma cell line. Cancer Lett 1996;101:143-148.
27. Brodie AM, Son C, King DA, Meyer KM, Inkster SE: Lack of evidence for aromatase in human prostatic tissues: Effects of 4-hydroxy-androstenedione and other inhibitors on androgen metabolism. Cancer Res 1989;49:6551-6555.
28. Negri-Cesi P, Motta M: Androgen metabolism in the human prostate cancer cell line LNCaP. J Steroid Biochem Mol Biol 1994;51:89-96.
29. Bulun SE, Mahendroo MS, Simpson ER: Polymerase chain reaction amplification fails to detect aromatase cytochrome P450 transcripts in normal human endometrium or decidua. J Clin Endocrinol Metab 1993;76:1458-1463.
30. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of proteins utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
31. Rambaldi A, Young D, Griffin JD: Expression of the M-CSF (CSF-1) gene by human monocytes. Blood 1987;69:1409-1413.
32. Poletti A, Rumio C, Rabuffetti M, Celotti F, Martini L: Type 1 5α-Reductase is localized in myelin membranes of male and female rats. Mol Cell Endocrinol 1997;129:181-190.
33. Poletti A, Celotti F, Motta M, Martini L: Characterization of rat 5α-reductase type 1 and type 2 expressed in Saccharomyces cerevisiae. Biochem J 1996;314:1047-1052.
34. Dlos S, Iehl C, Martin PM, Raynaud JP: Inhibition of the activity of "basic" 5α-reductase (type 1) detected in DU 145 cells and expressed in insect cells. J Steroid Biochem Mol Biol 1994;48: 347-352.
35. Smith CM, Ballard SA, Worman N, Buettner R, Masters JRW: 5α-reductase expression by prostate cancer cell lines and benign prostatic hyperplasia "in vitro." J Clin Endocrinol Metab 1996; 81:1361-1366.
36. Horoszewicz JS, Leong SS, Kawinsky E, Karr JP, Rosenthal H, Ming Chu T, Mirand EA, Murphy GP: LNCaP model for human prostate carcinoma. Cancer Res 1983;43:1809-1818.
37. Bonkhoff H, Stein U, Aumuller G, Remberger K: Differential expression of 5α-reductase isoenzymes in the human prostate and prostatic carcinomas. Prostate 1996;29:261-267.
38. McConnell JD, Wilson JD, George FW, Geller J, Pappas F, Stoner E: Finasteride, an inhibitor of 5α-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1992;74:505-508.
39. Sutkowski DM, Audia JE, Goode RL, Hsiao KC, Leibovitch IY, McNulty AM, Neubauer BL: Responses of LNCaP prostatic adenocarcinoma cell cultures to LY300502, a benzoquinolinone human type 1 5α-reductase inhibitor. Prostate 1996;Suppl 6:62-66.
40. Matzkin H, Soloway MS: Immunohistochemical evidence of the existence and localization of aromatase in human prostate tissues. Prostate 1992;21:309-314.